Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Metastatic Squamous Neck Cancer With Occult Primary
The prognosis for most treated cancer patients with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Deciding on further treatment depends on many factors, including the specific cancer, prior treatment, site of recurrence, as well as individual patient considerations. Treatments that are under clinical evaluation are appropriate and should be considered when possible. Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent metastatic squamous neck cancer with occult primary. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.General information about clinical trials is also available from the NCI Web site.
Nutrition in Cancer Care (PDQ®): Supportive care - Health Professional Information [NCI] - Current Clinical Trials
Check NCI's list of cancer clinical trials for U.S. supportive and palliative care trials about malnutrition, nutritional support and nutritional therapy that are now accepting participants. The list of trials can be further narrowed by location, drug, intervention, and other criteria. General information about clinical trials is also available from the NCI Web site.
Last Days of Life (PDQ®): Supportive care - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about patient care during the last days to last hours of life. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are
Nasopharyngeal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage II Nasopharyngeal Cancer
Standard treatment options:Chemoradiation therapy followed by adjuvant chemotherapy, as was used in the INT-0099 trial, for example.[Level of evidence: 3iiiA] (Patients with parapharyngeal extension were originally staged as T3 in the INT-0099 study and are now considered T2 in the current staging.)High-dose radiation therapy to the primary tumor site and prophylactic radiation therapy to the nodal drainage.Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage II nasopharyngeal cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.General information about clinical trials is also available from the NCI Web site.References: Cheng SH, Tsai SY, Yen KL, et al.: Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 18 (10): 2040-5, 2000. Xiao WW, Han F, Lu TX, et al.: Treatment outcomes after
Important It is possible that the main title of the report Bowen's Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Neuroblastoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Important It is possible that the main title of the report Astrocytoma, Malignant is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Medium and Large Choroidal Melanoma
Eye-sparing radiation therapy, either by plaque brachytherapy or external beam, is the preferred option for most patients with medium-sized choroidal melanoma. Enucleation remains the standard therapy for large, choroidal melanomas and melanomas that cause severe glaucoma or invade the optic nerve. Standard treatment options:Tumor growth pattern is a factor in the therapeutic decision. If there is a diffuse melanoma or if there is extraocular extension, enucleation should be considered, but radiation therapy can be employed for less extensive disease. Medium-sized choroidal melanomasPlaque radiation therapy.[1,2,3,4]External-beam, charged-particle radiation therapy: This approach is offered at specialized referral centers. It requires careful patient cooperation, with voluntary fixation of gaze.[5,6,7]Local eye-wall resection.[8,9]Combined therapy, with ablative laser coagulation or transpupillary thermotherapy to supplement plaque treatment.[10,11]Enucleation. This approach is
Topics in Complementary and Alternative Therapies (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Pharmacologic Treatments
714-X714-X is a chemical compound that contains camphor, a natural substance that comes from the wood and bark of the camphor tree. Nitrogen, water, and salts are added to camphor to make 714-X. It is claimed that 714-X protects the immune system and helps the body fight cancer. No peer-reviewed studies of 714-X has been published to show that it is safe or effective in treating cancer. See the PDQ patient summary on 714-X for more information.AntineoplastonsAntineoplastons are drugs made of chemical compounds that are naturally present in the urine and blood. It has been claimed that antineoplaston therapy can be used to stop certain cancer cells from dividing, while healthy cells are not affected.See the PDQ patient summary on Antineoplastons for more information.Cancell/Cantron/ProtocelCancell/Cantron/Protocel is a liquid that has been made in different forms since the late 1930s. It is also known by the names Sheridan's Formula, Jim's Juice, JS-114, JS-101, 126-F, and the
Neuroblastoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Neuroblastoma
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your child's doctor for clinical trials that are not listed here but may be right for your child.Low-Risk NeuroblastomaTreatment of low-risk neuroblastoma may include the following:Watchful waiting alone for certain infants.Surgery followed by watchful waiting.Surgery followed by combination chemotherapy, when serious health problems occur.Radiation therapy to treat tumors that are causing serious health problems and do not respond quickly to chemotherapy.Intermediate-Risk NeuroblastomaTreatment of intermediate-risk neuroblastoma may include the following:Surgery alone.Surgery followed by chemotherapy. Sometimes a second surgery is needed.Watchful waiting alone for certain infants.Surgery followed by chemotherapy. Radiation therapy may given to treat tumors that are causing serious health problems and do not respond